Neurostudija - Company finances
|
EUR
|
2019
From: 2019-03-08
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|
|
Financial data
|
|||||||
| Sales revenue | - | 79,316 | 115,326 | 124,307 | 145,371 | 220,358 | 261,172 |
| Profit before tax | -7,544 | 4,278 | 10,396 | 29,743 | 24,476 | 15,612 | -11,884 |
| Net profit | -7,544 | 4,278 | 10,063 | 28,253 | 23,234 | 14,741 | -11,884 |
| Equity | -5,044 | -766 | 9,297 | 37,550 | 60,784 | 39,526 | 27,642 |
| Liabilities | 61,714 | 68,186 | 48,891 | 14,063 | 3,686 | 32,889 | 20,829 |
| Non-current assets | 53,956 | 49,080 | 40,408 | 30,762 | 21,943 | 29,844 | 17,656 |
| Current assets | 2,600 | 18,199 | 17,665 | 20,065 | 41,620 | 41,707 | 29,906 |
| Total assets | 56,556 | 67,279 | 58,073 | 50,827 | 63,563 | 71,551 | 47,562 |
|
Taxes paid
|
|||||||
| STI taxes | - | - | - | - | 13,649 | 30,597 | 33,241 |
| Social insurance contributions | - | - | - | - | 11,876 | 29,316 | 35,381 |
|
Financial indicators
|
|||||||
| Revenue change y/y | - | - | +45.4% | +7.8% | +16.9% | +51.6% | +18.5% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -13.3% | 6.4% | 17.3% | 55.6% | 36.6% | 20.6% | -25.0% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | - | 108.2% | 75.2% | 38.2% | 37.3% | -43.0% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | 5.4% | 8.7% | 22.7% | 16.0% | 6.7% | -4.6% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | 5.4% | 9.0% | 23.9% | 16.8% | 7.1% | -4.6% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | 5.3 | 0.4 | 0.1 | 0.8 | 0.8 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | 23,795 | 31,452 | 40,316 | 32,914 | 41,317 | 44,141 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Neurostudija - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2025-05-04 | 2025-05-06 | 0.31 |
| 2025-04-24 | 2025-04-29 | 0.31 |
Neurostudija - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-02-20 | 2025-02-27 | 16.0 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Neurostudija, UAB (code 305064718) is a private limited liability company engaged in medical specialists activities. In 2025, the company generated revenue of €261.2K, increasing by 18.5% year on year and by 79.7% over two years. Despite this growth, profitability weakened materially: net loss amounted to €11.9K, compared with net profit of €14.7K in 2024 and €23.2K in 2023. The profit margin in 2025 was -4.6%, after 6.7% in 2024 and 16.0% in 2023. Total assets declined to €47.6K from €71.6K a year earlier, while equity decreased to €27.6K and liabilities stood at €20.8K. The equity ratio was 58.1% and debt-to-equity 0.75, suggesting a moderate capital structure even though results turned negative. Asset turnover reached 5.49x, indicating strong revenue generation relative to the asset base. Revenue per employee was €52.2K, while profit per employee was negative at €2.4K. Overall, 2025 shows continued sales expansion but a clear deterioration in earnings and balance sheet size.